Table 1. Patient characteristics.
| Data a (n) | Total cohort | Not infected | Any infection | P-value b | |
|---|---|---|---|---|---|
| Age; years (mean, SD c ) | 250 | 41.9 (12.0) | 42.6 (12.4) | 40.3 (10.9) | 0.18 |
| Sex (female)(n, %) | 252 | 169 (67.1) | 127 (72.6) | 42 (54.5) | 0.005 |
| Residence (n,%) | 249 | 0.004 | |||
| - Rural | 76 (30.5) | 43 (24.7) | 44.0) | ||
| - Semi-urban | 148 (59.4) | 111 (63.8) | 49.3) | ||
| - Urban | 25 (10.0) | 20 (11.5) | 5 (6.7) | ||
| Educational level (n, %) | 243 | 0.07 | |||
| - Lower than primary | 23 (9.5) | 15 (8.9) | (10.8) | ||
| - Primary | 66 (27.2) | 40 (23.7) | 35.1) | ||
| - Secondary | 8.3) | 108 (63.9) | 52.7) | ||
| - Tertiary/higher | 7 (2.8) | 6 (3.6) | 1 (1.4) | ||
| CD4 count; cells/μL (median, IQR d ) | 247 | 366 (177–555) | 345(159–531) | 382(185–579) | 0.85 |
| CD4 count stratified (n,%) | 0.99 | ||||
| - 0–100 cells/μL | 36 (14.6) | 21 (12.4) | 19.5) | ||
| - 101–200 cells/μL | 33 (13.4) | 27 (15.9) | (7.8) | ||
| - 201–350 cells/μL | 51 (20.6) | 38 (22.4) | 16.9) | ||
| - >351 cells/μL | 127 (51.4) | 84 (49.4) | 43 (55.8) | ||
| Hemoglobin; g/dL (median, IQR d ) | 160 | 10.0 (10.0–12.0) | 11.0 (10.0–12.0) | 11.7 (10.7–12.7) | 0.07 |
| On ART e >12 weeks (n, %) | 252 | 149 (59.1) | 111 (63.4) | 38 (49.4) | 0.04 |
| On CTX-P f (n, %) | 222 | 103 (46.4) | 76 (47.8) | 27 (42.9) | 0.51 |
| Antihelminth treatment <12 weeks (n, %) | 151 | 53 (35.1) | 38 (36.5) | 15 (31.9) | 0.58 |
Characteristics of those patients who were diagnosed with one or more helminth infections versus those who had negative test results.
a The first column shows for how many patients data were complete for each respective variable.
b P-values were calculated using the χ² test was used for categorical variables (ordinal χ² test if more than 2 categories), the Students' T test for linear normally distributed variables, and Mann Whitney U for non-parametric variables.
c Standard deviation (SD),
d Interquartile range (IQR),
e Anti-retroviral therapy (ART),
f Cotrimoxazole preventive therapy (CTX-P).